Industry

PHOENIX–(BUSINESS WIRE)–At this year’s American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies focused on glucagon-like peptide-1 (GLP-1) agonist usage in patients undergoing surgery. GLP-1 agonists are a class of medications commonly prescribed to treat type 2 diabetes and obesity, and their therapeutic … [Read more…]

PHOENIX–(BUSINESS WIRE)–At this year’s American Society of Regional Anesthesia and Acute Pain Medicine (ASRA) annual meeting, investigators at Hospital for Special Surgery (HSS) presented significant studies leveraging artificial intelligence (AI) to provide insights into long-term pain risk after surgery and what patients want to know about anesthesia. These insights may ultimately help guide anesthesiologists’ consultations … [Read more…]

-Efficacy and safety data shared at IMMUNOLOGY2026 reinforce potential of ZL-1503 as a first-in-class treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Strong inhibition of both inflammatory and pruritic pathways over 112 days following a single dose of ZL-1503, together with a favorable preclinical safety profile, supports potential for less frequent dosing … [Read more…]

TORONTO–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions. The updated release reads: MOUNTAIN VALLEY MD ANNOUNCES APPOINTMENT OF ADVISORS AND STOCK OPTION GRANTS Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) announces that it is issuing this amended and updated news release to correct … [Read more…]

$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the closing of its previously announced private placement … [Read more…]

Ultrasensitive, structural variant-based ctDNA monitoring reliably tracks therapeutic response and predicts progression in metastatic breast cancer, and is a strong independent prognostic marker in advanced ovarian cancers MORRISVILLE, N.C.–(BUSINESS WIRE)–#AACR—SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for early molecular residual disease (MRD) detection, today announced that the company … [Read more…]

Gathering at United Therapeutics headquarters in Silver Spring, MD catalyzes interdisciplinary collaboration, highlighting quantum mechanics’ role in health and disease MANHASSET, N.Y.–(BUSINESS WIRE)–What if healing wasn’t just about chemistry, but about the very energy and light within our bodies? This groundbreaking question guided Northwell Health’s Quantum Biology Forum, a seminal first meeting of minds held … [Read more…]

NEW YORK–(BUSINESS WIRE)–Colgate-Palmolive Company (NYSE:CL) will provide a live webcast of its 2026 first quarter earnings conference call on Friday, May 1, 2026, at 8:30 a.m. ET. The call will be hosted by Chairman, President and CEO, Noel Wallace, Chief Financial Officer, Stan Sutula, Executive Vice President, Investor Relations, Claire Ross, and Executive Vice President, … [Read more…]

Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to host an analyst event following the presentation of its late-breaking data at the Heart Rhythm Society on … [Read more…]

Establishing an innovative class of polyomavirus antivirals spanning BK and JC virus indications CANTON, Mass.–(BUSINESS WIRE)–#BKV–Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus infections are a major cause … [Read more…]